Name: UMIN ID:
Unique ID issued by UMIN | UMIN000033560 |
---|---|
Receipt number | R000038274 |
Scientific Title | TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H). |
Date of disclosure of the study information | 2018/08/10 |
Last modified on | 2023/02/01 09:05:56 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/07/30 16:31:14 | ||
2 | Update | 2018/09/19 08:35:52 | Recruitment status Anticipated trial start date |
|
3 | Update | 2019/01/28 10:32:25 | Institutions |
|
4 | Update | 2019/08/01 14:17:59 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
5 | Update | 2019/08/01 14:24:26 | Organization |
|
6 | Update | 2020/02/02 12:46:09 | Date of IRB Last follow-up date |
|
7 | Update | 2021/02/08 16:15:08 | Last follow-up date |
|
8 | Update | 2021/07/30 11:36:14 | Last follow-up date |
|
9 | Update | 2021/08/02 09:33:37 | Condition Condition |
|
10 | Update | 2022/02/09 16:56:49 | Primary outcomes Primary outcomes |
|
11 | Update | 2022/06/21 10:52:42 | Recruitment status Date of IRB |
|
12 | Update | 2023/02/01 09:05:56 | Number of participants that the trial has enrolled |